Asunto(s)
Linfoma de Células T/patología , Distribución por Edad , Antígenos CD/análisis , Antígenos de Neoplasias/análisis , Biopsia con Aguja , Aberraciones Cromosómicas , Diagnóstico Diferencial , Reordenamiento Génico de Linfocito T , Enfermedad de Hodgkin/diagnóstico , Humanos , Inmunofenotipificación , Ganglios Linfáticos/patología , Linfadenitis/diagnóstico , Linfoma de Células T/química , Linfoma de Células T/diagnóstico , Linfoma de Células T/epidemiología , Masculino , Persona de Mediana Edad , Proteínas de Fusión Oncogénica/genéticaAsunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Neoplasias de la Médula Ósea/tratamiento farmacológico , Etopósido/administración & dosificación , Neoplasias Pulmonares/tratamiento farmacológico , Linfoma de Células T/tratamiento farmacológico , Paniculitis/tratamiento farmacológico , Administración Oral , Anciano de 80 o más Años , Biomarcadores de Tumor/análisis , Biopsia , Neoplasias de la Médula Ósea/química , Neoplasias de la Médula Ósea/patología , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/química , Neoplasias Pulmonares/patología , Linfoma de Células T/química , Linfoma de Células T/patología , Masculino , Paniculitis/patología , Resultado del TratamientoRESUMEN
Macrocyclic monoacyl lathyrane derivatives bearing a benzoyl moiety were previously found to be strong ABCB1 modulators. To explore the effects of different substituents of the aromatic moiety, 14 new compounds (1.1-1.7, 1.10, and 2.1-2.4) were prepared from jolkinol D (1), obtained from Euphorbia piscatoria, and from jolkinodiol (2), its hydrolysis derivative. Compounds 1.8 and 1.9, having aliphatic moieties, were also obtained. The reversal of ABCB1-mediated MDR was evaluated through functional and chemosensitivity assays on the human ABCB1-gene-transfected L5178Y mouse T-lymphoma cell line. Structure-activity relationships showed that addition of electron-donating groups to the aromatic moiety improved the activity. The effects on the ATPase activity of the strongest modulator (1.3) and the inactive jolkinol D (1) were also investigated and compared. Moreover, in the chemosensitivity assay, most of the compounds interacted synergistically with doxorubicin. Compounds 1.1-1.10 and 2.1-2.4 were further assessed for their collateral sensitivity effect against the human cancer cells: EPG85-257 (gastric) and EPP85-181 (pancreatic), and the matching drug-selected cells EPG85-257RDB, EPG85-257RNOV, EPP85-181RDB, and EPP85-181RNOV. The most promising ones (1.8 and 1.10) along with compound 3, previously selected, were investigated as apoptosis inducers. The compounds were able to induce apoptosis through caspase-3 activation, with significant differences being observed between the parental and resistant cells.
Asunto(s)
Antineoplásicos Fitogénicos/aislamiento & purificación , Antineoplásicos Fitogénicos/farmacología , Apoptosis/efectos de los fármacos , Caspasa 3/metabolismo , Diterpenos/aislamiento & purificación , Diterpenos/farmacología , Doxorrubicina/farmacología , Resistencia a Antineoplásicos/efectos de los fármacos , Euphorbia/química , Linfoma de Células T/tratamiento farmacológico , Compuestos Macrocíclicos/aislamiento & purificación , Compuestos Macrocíclicos/farmacología , Subfamilia B de Transportador de Casetes de Unión a ATP/química , Subfamilia B de Transportador de Casetes de Unión a ATP/metabolismo , Animales , Antineoplásicos Fitogénicos/química , Caspasa 3/química , Línea Celular Tumoral , Diterpenos/química , Doxorrubicina/química , Humanos , Linfoma de Células T/química , Compuestos Macrocíclicos/química , Ratones , Estructura Molecular , Relación Estructura-ActividadRESUMEN
An overview of the pathology of extranodal lymphoma is presented. The emphasis of this presentation is on the classification system of extranodal lymphomas, including both B-cell and T-cell lymphomas, based on their morphology, phenotype, and molecular alterations.
Asunto(s)
Biomarcadores de Tumor/análisis , Linfoma de Células B/química , Linfoma de Células B/patología , Linfoma de Células T/química , Linfoma de Células T/patología , Linfocitos B/química , Linfocitos B/patología , Diagnóstico Diferencial , Medicina Basada en la Evidencia , Humanos , Linfocitos T/química , Linfocitos T/patologíaRESUMEN
T lymphocyte non-Hodgkin's lymphoma (T-NHL) represents an aggressive and largely therapy-resistant subtype of lymphoid malignancies. As deregulated apoptosis is a frequent hallmark of lymphomagenesis, we analyzed gene expression profiles and protein levels of primary human T-NHL samples for various apoptotic regulators. We identified the apoptotic regulator MCL-1 as the only pro-survival BCL-2 family member to be highly expressed throughout all human T-NHL subtypes. Functional validation of pro-survival protein members of the BCL-2 family in two independent T-NHL mouse models identified that the partial loss of Mcl-1 significantly delayed T-NHL development in vivo. Moreover, the inducible reduction of MCL-1 protein levels in lymphoma-burdened mice severely impaired the continued survival of T-NHL cells, increased their susceptibility to chemotherapeutics and delayed lymphoma progression. Lymphoma viability remained unaffected by the genetic deletion or pharmacological inhibition of all alternative BCL-2 family members. Consistent with a therapeutic window for MCL-1 treatment within the context of the whole organism, we observed an only minimal toxicity after systemic heterozygous loss of Mcl-1 in vivo. We conclude that re-activation of mitochondrial apoptosis by blockade of MCL-1 represents a promising therapeutic strategy to treat T-cell lymphoma.
Asunto(s)
Proteínas Reguladoras de la Apoptosis/genética , Apoptosis , Linfoma de Células T/química , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/análisis , Animales , Proteínas Reguladoras de la Apoptosis/análisis , Supervivencia Celular , Resistencia a Antineoplásicos , Perfilación de la Expresión Génica , Humanos , Linfoma de Células T/patología , Ratones , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/antagonistas & inhibidores , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/genética , Proteína 1 de la Secuencia de Leucemia de Células Mieloides/fisiología , Proteínas Proto-Oncogénicas c-bcl-2/genéticaRESUMEN
MUM1 is a member of the interferon regulatory factor family of transcription factors. It is normally expressed in plasma cells, late B cells, and activated T cells, and has been described in several B-cell malignancies and some T-cell neoplasms. The aim of our study was to evaluate the role of MUM-1/IRF4 protein in differentiating angioimmunoblastic T cell lymphoma (AITL) with Hodgkin/Reed-Sternberg (HRS)-like cells from cHL. We identified 12 cases of AITL with HRS-like cells and 24 cases of cHL from March 2013 to November 2014. IHC for MUM-1/IRF4 protein was performed on the tissue of these cases and some relevant positive and negative controls. MUM-1 was expressed in HRS-like cells and some neoplastic T-cells in AITL with HRS-like cells (12/12, 100%) and formed the rosettes around the HRS-like cells (12/12, 100%), expressed in HRS cells in classic Hodgkin Lymphoma (cHL) (24/24, 100%) and just one case formed rosettes around the HRS cells (1/24, 4.2%). Based on the results, MUM-1 could be a useful marker for the differential diagnosis between AITL with HRS-like cells and cHL.
Asunto(s)
Biomarcadores de Tumor/análisis , Enfermedad de Hodgkin/metabolismo , Linfadenopatía Inmunoblástica/metabolismo , Factores Reguladores del Interferón/análisis , Linfoma de Células T/química , Células de Reed-Sternberg/química , Biopsia , Diagnóstico Diferencial , Herpesvirus Humano 4/genética , Enfermedad de Hodgkin/genética , Enfermedad de Hodgkin/patología , Enfermedad de Hodgkin/virología , Humanos , Linfadenopatía Inmunoblástica/genética , Linfadenopatía Inmunoblástica/patología , Linfadenopatía Inmunoblástica/virología , Inmunohistoquímica , Hibridación in Situ , Linfoma de Células T/genética , Linfoma de Células T/patología , Linfoma de Células T/virología , Valor Predictivo de las Pruebas , ARN Viral/genética , Células de Reed-Sternberg/patología , Células de Reed-Sternberg/virología , Estudios RetrospectivosRESUMEN
S100 T-cell lymphomas are infrequent, and except 1 all have been CD4 negative. On the basis of an index case of CD4 S100 T-cell prolymphocytic leukemia (T-PLL), we studied S100 protein expression in 19 additional T-PLLs and 56 other T-cell lymphomas that are usually CD4, including 15 angioimmunoblastic T-cell lymphomas, 24 anaplastic large cell lymphomas (16 ALK and 8 ALK), 7 mycosis fungoides/Sézary syndrome, and 10 peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS). Two additional S100 CD4 PTCL, NOS cases were also reviewed. Thirty percent (6/20) of T-PLLs were S100 compared with 0/56 other T-cell lymphomas with previously unstudied S100 reactivity (40 CD4, 2 CD8, 11 CD4/CD8, 3 unknown) (P=0.0007). There were no significant differences between the S100 and S100 T-PLLs with regard to the male:female ratio (2:1 vs. 1:1), age (71.6±7.7 vs. 65.4±9.3), peripheral blood lymphocyte count (67.2±116.6 vs. 101.1±159.7×10/L), or median survival (463 vs. 578 d, where known). The 2 S100 PTCL, NOS cases occurred in a 7-year-old boy and a 45-year-old woman. Both had involvement of the bone marrow and peripheral blood but were morphologically unlike T-PLL and lacked TCL1 gene rearrangement. These results demonstrate that S100 T-cell lymphomas include a subset that are CD4 and most often, but not exclusively, are T-PLL. Although having diagnostic implications, there were no documented clinical differences between the S100 and S100 T-PLLs.
Asunto(s)
Biomarcadores de Tumor/análisis , Linfocitos T CD4-Positivos/química , Leucemia Prolinfocítica de Células T/metabolismo , Linfoma de Células T/química , Proteínas S100/análisis , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/genética , Biopsia , Linfocitos T CD4-Positivos/inmunología , Niño , Femenino , Humanos , Inmunohistoquímica , Hibridación Fluorescente in Situ , Estimación de Kaplan-Meier , Leucemia Prolinfocítica de Células T/genética , Leucemia Prolinfocítica de Células T/inmunología , Leucemia Prolinfocítica de Células T/mortalidad , Leucemia Prolinfocítica de Células T/patología , Linfoma de Células T/genética , Linfoma de Células T/inmunología , Linfoma de Células T/mortalidad , Linfoma de Células T/patología , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , PronósticoRESUMEN
Primary central nervous system (CNS) lymphomas are relatively rare with the most common subtype being diffuse large B-cell lymphoma. Primary CNS T-cell lymphomas (PCNSTL) account for <5% of CNS lymphomas. We report the clinical, morphologic, immunophenotypic, and molecular characteristics of 18 PCNSTLs. Fifteen cases were classified as peripheral T-cell lymphoma, not otherwise specified, 2 of which were of γδ T-cell derivation and 1 was TCR silent; there was 1 anaplastic large cell lymphoma, ALK-positive and 2 anaplastic large cell lymphoma, ALK-negative. Median age was 58.5 years (range, 21 to 81 y), with an M:F ratio of 11:7. Imaging results showed that 15 patients had supratentorial lesions. Regardless of subtype, necrosis and perivascular cuffing of tumor cells were frequently observed (11/18 cases). CD3 was positive in all cases but 1; 10/17 were CD8-positive, and 5/17 were CD4-positive. Most cases studied had a cytotoxic phenotype with expression of TIA1 (13/15) and granzyme-B (9/13). Polymerase chain reaction analysis of T-cell receptor γ rearrangement confirmed a T-cell clone in 14 cases with adequate DNA quality. Next-generation sequencing showed somatic mutations in 36% of cases studied; 2 had >1 mutation, and none showed overlapping mutations. These included mutations in DNMT3A, KRAS, JAK3, STAT3, STAT5B, GNB1, and TET2 genes, genes implicated previously in other T-cell neoplasms. The outcome was heterogenous; 2 patients are alive without disease, 4 are alive with disease, and 6 died of disease. In conclusion, PCNSTLs are histologically and genomically heterogenous with frequent phenotypic aberrancy and a cytotoxic phenotype in most cases.
Asunto(s)
Biomarcadores de Tumor , Neoplasias del Sistema Nervioso Central/diagnóstico , Inmunofenotipificación , Linfoma de Células T/diagnóstico , Técnicas de Diagnóstico Molecular , Linfocitos T , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Biopsia , Neoplasias del Sistema Nervioso Central/química , Neoplasias del Sistema Nervioso Central/genética , Neoplasias del Sistema Nervioso Central/inmunología , Neoplasias del Sistema Nervioso Central/mortalidad , Neoplasias del Sistema Nervioso Central/patología , Análisis Mutacional de ADN , Femenino , Reordenamiento Génico de la Cadena delta de los Receptores de Antígenos de los Linfocitos T , Reordenamiento Génico de la Cadena gamma de los Receptores de Antígenos de los Linfocitos T , Predisposición Genética a la Enfermedad , Humanos , Inmunohistoquímica , Hibridación in Situ , Linfoma de Células T/química , Linfoma de Células T/genética , Linfoma de Células T/inmunología , Linfoma de Células T/mortalidad , Linfoma de Células T/patología , Masculino , Persona de Mediana Edad , Mutación , Fenotipo , Reacción en Cadena de la Polimerasa , Valor Predictivo de las Pruebas , Pronóstico , Receptores de Antígenos de Linfocitos T gamma-delta/genética , Linfocitos T/química , Linfocitos T/inmunología , Linfocitos T/patología , Factores de Tiempo , Adulto JovenRESUMEN
A 7-year-old boy with no history of malnutrition or diarrhoea complained of acute abdominal pain, was diagnosed with acute appendicitis, and underwent appendectomy. Histologically, a diffuse infiltrate of large atypical lymphoid cells was found in the entire appendiceal wall. Immunohistochemical examination revealed that the tumour cells expressed T-cell receptor (TCR)-ßF1, CD3, CD4, CD25, cytotoxic-related protein TIA1 and granzyme-B, but were negative for CD8, Foxp3, CD20, CD30 and CD56. Polymerase chain reaction (PCR) revealed clonal bands of TCR-γ gene products in the tumour tissue. No anti-cytomegalovirus antibody-positive cells were detected. In situ hybridization revealed no nuclear signals of Epstein-Barr virus (EBV)-encoded RNA. Helicobacter pylori infection was detected in tumour tissue by anti-East Asian cytotoxin-associated gene (Cag) A antibody and PCR using its specific primers. The patient received chemotherapy and has remained in remission for 2 years. To the best of our knowledge, only two cases of appendiceal T-cell non-Hodgkin lymphoma (NHL) have been reported, both in elderly patients. We believe that this is the first reported case of childhood CD4- and TIA1-positive cytotoxic T (Th1)-cell NHL in the appendix or gastrointestinal tract. Helicobacter pylori infection might be an initiator of atypical cytotoxic T-cell proliferation. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1302380563830412.
Asunto(s)
Neoplasias del Apéndice/patología , Linfoma de Células T/patología , Dolor Abdominal/etiología , Apendicectomía , Neoplasias del Apéndice/química , Neoplasias del Apéndice/complicaciones , Neoplasias del Apéndice/genética , Neoplasias del Apéndice/microbiología , Neoplasias del Apéndice/cirugía , Apendicitis/etiología , Biomarcadores de Tumor/análisis , Biomarcadores de Tumor/genética , Quimioterapia Adyuvante , Niño , Genes Codificadores de la Cadena gamma de los Receptores de Linfocito T , Helicobacter pylori/aislamiento & purificación , Humanos , Inmunohistoquímica , Linfoma de Células T/química , Linfoma de Células T/complicaciones , Linfoma de Células T/genética , Linfoma de Células T/microbiología , Linfoma de Células T/cirugía , Masculino , Reacción en Cadena de la Polimerasa , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Edema/etiología , Linfoma de Células T/diagnóstico , Paniculitis/diagnóstico , Tejido Subcutáneo/patología , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/análisis , Biopsia , Edema/patología , Cara , Femenino , Humanos , Inmunohistoquímica , Linfoma de Células T/química , Linfoma de Células T/complicaciones , Linfoma de Células T/terapia , Imagen Multimodal , Paniculitis/complicaciones , Paniculitis/terapia , Tomografía de Emisión de Positrones , Valor Predictivo de las Pruebas , Recurrencia , Trasplante de Células Madre , Tejido Subcutáneo/química , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-cell lymphoma since its initial characterization. We have shown that angioimmunoblastic T-cell lymphoma endothelial cells produce vascular endothelial growth factor-A (VEGFA), and participate in lymphoma progression. In squamous cell carcinoma, endothelial BCL2 expression induces a crosstalk with tumor cells through VEGFA, a major mediator of tumoral angiogenesis. In the present study, we analyzed BCL2 and VEGFA in 30 angioimmunoblastic T-cell lymphomas, using triple immunofluorescence to identify protein coexpression in well-characterized lymphoma cells and microenvironment neoangiogenic endothelial cells. Using quantitative real-time PCR, we assessed mRNA expression levels in laser-microdissected endothelial and lymphoma cells. In lymphoma cells, as in endothelial cells, BCL2 and VEGFA proteins were coexpressed. BCL2 was expressed only in neoangiogenic CD34(+)CD105(+) endothelial cells. In laser-microdissected cells, mRNA studies showed a significant relationship between BCL2 and VEGFA levels in CD34(+) endothelial cells, but not in CD3(+)CD10(+)lymphoma cells, or in CD34(+) endothelial cells from lymph node hyperplasia. Further study showed that, in AITL, BCL2 mRNA levels in CD34(+)CD105(+) neoangiogenic endothelial cells also correlated with microvessel density, International Prognostic Index, Ann Arbor stage, bone marrow involvement and elevated LDH. BCL2 expression by CD105(+) neoangiogenic endothelial cells is related to tumor progression in angioimmunoblastic T-cell lymphoma.
Asunto(s)
Antígenos CD/análisis , Biomarcadores de Tumor/análisis , Células Endoteliales/química , Linfadenopatía Inmunoblástica/metabolismo , Ganglios Linfáticos/química , Linfoma de Células T/química , Microvasos/química , Proteínas Proto-Oncogénicas c-bcl-2/análisis , Receptores de Superficie Celular/análisis , Adulto , Anciano , Anciano de 80 o más Años , Antígenos CD34/análisis , Biomarcadores de Tumor/genética , Estudios de Casos y Controles , Distribución de Chi-Cuadrado , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Endoglina , Células Endoteliales/inmunología , Células Endoteliales/patología , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Linfadenopatía Inmunoblástica/genética , Linfadenopatía Inmunoblástica/inmunología , Linfadenopatía Inmunoblástica/mortalidad , Linfadenopatía Inmunoblástica/patología , Linfadenopatía Inmunoblástica/terapia , Estimación de Kaplan-Meier , Captura por Microdisección con Láser , Ganglios Linfáticos/irrigación sanguínea , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/patología , Linfoma de Células T/genética , Linfoma de Células T/inmunología , Linfoma de Células T/mortalidad , Linfoma de Células T/patología , Linfoma de Células T/terapia , Masculino , Microvasos/inmunología , Microvasos/patología , Persona de Mediana Edad , Análisis Multivariante , Neovascularización Patológica , Paris , Modelos de Riesgos Proporcionales , Proteínas Proto-Oncogénicas c-bcl-2/genética , ARN Mensajero/análisis , Reacción en Cadena en Tiempo Real de la Polimerasa , Medición de Riesgo , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento , Microambiente Tumoral , Factor A de Crecimiento Endotelial Vascular/análisis , Factor A de Crecimiento Endotelial Vascular/genéticaAsunto(s)
Antígenos CD20/análisis , Ceguera/diagnóstico , Exoftalmia/diagnóstico , Linfoma de Células T/patología , Neoplasias Orbitales/patología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/análisis , Femenino , Humanos , Linfoma de Células T/química , Linfoma de Células T/tratamiento farmacológico , Imagen por Resonancia Magnética , Persona de Mediana Edad , Neoplasias Orbitales/química , Neoplasias Orbitales/tratamiento farmacológico , Dolor/diagnóstico , Tomografía Computarizada por Rayos X , Agudeza VisualRESUMEN
PURPOSE: An unusual case of nasal-type natural killer/T-cell lymphoma (NKTL) of the orbit is reported. METHODS: The clinical history, computed tomography, magnetic resonance imaging, and biopsy specimen of a 29-year-old man with a right orbital lymphoma were evaluated. RESULTS: The patient initially presented with conjunctival injection and had flu-like symptoms before developing right proptosis and reduced vision; imaging showed a diffuse infiltrative process throughout the orbit. Orbital biopsy revealed angiodestruction with prominent necrosis, and angiocentric lymphoma growth and lymphoma cells were positively stained for CD3, CD20, CD45RO, CD56, cytotoxic molecules (granzyme B and T-cell intracellular antigen-1), and Epstein-Barr virus. CONCLUSIONS: NKTL is rare and may present acutely; the imaging findings presented serve to highlight the radiologic features of the disease.
Asunto(s)
Células Asesinas Naturales/patología , Linfoma de Células T/diagnóstico , Neoplasias Orbitales/diagnóstico , Adulto , Antígenos CD/análisis , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/análisis , Enfermedades de la Conjuntiva/diagnóstico , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Exoftalmia/diagnóstico , Glucocorticoides/uso terapéutico , Humanos , Linfoma de Células T/química , Linfoma de Células T/tratamiento farmacológico , Imagen por Resonancia Magnética , Masculino , Neoplasias Orbitales/química , Neoplasias Orbitales/tratamiento farmacológico , Prednisona/uso terapéutico , Tomografía Computarizada por Rayos X , Vincristina/uso terapéutico , Trastornos de la Visión/diagnósticoRESUMEN
PURPOSE Disease dissemination to the bone marrow is detected at diagnosis in approximately 15% of children with T-cell lymphoblastic lymphoma (T-LL). It is unclear whether the remaining patients have submicroscopic systemic disease and, if so, what is the clinical significance of this finding. PATIENTS AND METHODS Using a flow cytometric method that can detect one T-LL cell among 10,000 normal cells, we examined bone marrow and peripheral-blood samples collected from 99 children with T-LL at diagnosis, as well as blood samples collected from 42 patients during treatment. Results In 71 (71.7%) of the 99 marrow samples obtained at diagnosis, T-LL cells represented 0.01% to 31.6% (median, 0.22%) of mononuclear cells; 57 of the 71 T-LL-positive samples were from patients with stage II/III disease. Results of studies in bilateral marrow aspirates were highly concordant. Two-year event-free survival (EFS) was 68.1% +/- 11.1% (SE) for patients with > or = 1% T-LL cells in bone marrow versus 90.7% +/- 4.4% for those with lower levels of marrow involvement (P = .031); EFS for patients with > or = 5% lymphoblasts was 51.9% +/- 18.0% (P = .009). T-LL cells were as prevalent in blood as in marrow; monitoring residual T-LL cells in blood during remission induction therapy identified patients with slower disease clearance. CONCLUSION More than two thirds of children with T-LL have disseminated disease at diagnosis, a proportion much higher than previously demonstrated. Measurements of disease dissemination at diagnosis might provide useful prognostic information, which can be further refined by monitoring response to therapy through blood testing.
Asunto(s)
Transmisión de Enfermedad Infecciosa , Linfoma de Células T/química , Leucemia-Linfoma Linfoblástico de Células Precursoras B , Leucemia-Linfoma Linfoblástico de Células T Precursoras , Acondicionamiento Pretrasplante , Células de la Médula Ósea , Enfermedades de la Médula Ósea/microbiología , Niño , Citometría de Flujo , Humanos , Linfoma de Células B/sangre , Linfoma no Hodgkin , Leucemia-Linfoma Linfoblástico de Células Precursoras B/sangre , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Leucemia-Linfoma Linfoblástico de Células T Precursoras/sangreRESUMEN
PURPOSE: To document fully the first credible primary T-cell lymphoma of the retina and central nervous system in a 71-year-old man. DESIGN: Interventional, retrospective report. METHODS: Critical analysis of clinical history and findings, which included bilateral vitreitis with anterior chamber reaction, creamy intraretinal infiltrates, and retinal detachment; complete blood counts and other blood studies (anti-neutrophil cytoplasmic antibody [ANCA], angiotensin-converting enzyme levels, and Lyme and fluorescent treponemal antibody absorption titers); magnetic resonance imaging (MRI) scanning of the brain with total body computed tomographic and positron emission tomographic scanning; interleukin (IL) level determinations (IL-10 and IL-6); cytologic and electron microscopic evaluations; immunophenotyping of cells; and polymerase chain reaction studies for viral deoxyribonucleic acid and ribonucleic acid, and immunoglobulin heavy-chain, and T-cell receptor (TCR) gene rearrangements. RESULTS: The first vitreous specimen was diagnosed mistakenly as cytologically reactive and contained elevated levels of IL-10 and IL-6 in a ratio of 7 to 1. T cells predominated on immunophenotypic analysis. Computed tomographic and positron emission tomographic whole body scanning showed negative results for lymphoma. An MRI scan of the brain eventually revealed a cerebellar lesion. A retinal biopsy harbored cytologically atypical pleomorphic cells that were almost all immunophenotypically T cells; polymerase chain reaction studies demonstrated a clonal TCR gene rearrangement. T-cell lymphocytes in the biopsy specimen of the cerebellum had an identical clonal TCR gene rearrangement. CONCLUSIONS: This case unequivocally establishes that primary retinal T-cell lymphoma accompanied by central nervous system involvement can occur. Elevation in the IL-10 to IL-6 ratio in the face of inconclusive or confusing vitreous cytologic and immunophenotypic findings (a predominance of "reactive T cells with some atypicality") should lead to gene rearrangement studies on biopsies of involved tissues for the detection of T-cell clonality.
Asunto(s)
Neoplasias Cerebelosas/patología , Reordenamiento Génico de Linfocito T/genética , Inmunofenotipificación , Linfoma de Células T/patología , Receptores de Antígenos de Linfocitos T/genética , Neoplasias de la Retina/patología , Linfocitos T/inmunología , Anciano , Biomarcadores de Tumor/análisis , Neoplasias Cerebelosas/química , Neoplasias Cerebelosas/genética , Neoplasias Cerebelosas/inmunología , Líquido Cefalorraquídeo/citología , Líquido Cefalorraquídeo/inmunología , Ensayo de Inmunoadsorción Enzimática , Resultado Fatal , Humanos , Cadenas Pesadas de Inmunoglobulina/genética , Interleucina-10/sangre , Interleucina-6/sangre , Linfoma de Células T/química , Linfoma de Células T/genética , Linfoma de Células T/inmunología , Imagen por Resonancia Magnética , Masculino , Reacción en Cadena de la Polimerasa , Neoplasias de la Retina/química , Neoplasias de la Retina/genética , Neoplasias de la Retina/inmunología , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Cuerpo Vítreo/inmunología , Cuerpo Vítreo/patologíaRESUMEN
Intestinal T-cell lymphoma is a heterogenous group. These tumors differ in their association with enteropathy, intraepithelial or nonintraepithelial origin, primary or secondary involvement, and T-cell or natural killer-like T-cell immunophenotype. There are also nonneoplastic conditions, such as celiac disease, refractory sprue, and reactive T-cell infiltration that mimic intestinal T-cell lymphoma. Therefore, the differential diagnosis requires extensive morphologic, immunophenotypic, and molecular genetic studies. A subset of primary intestinal intraepithelial T-cell lymphoma has emerged in recent years that is distinguished from enteropathy-type T-cell lymphoma in terms of clinical presentation (nonenteropathic), morphology (monomorphic small to medium-sized cells), immunophenotype (CD3(-)CD8(+)CD56(+)), and cytogenetics. We report such a case with a unique immunophenotype (CD3(-), cytoplasmic CD3(+), CD4(-), CD8(+), CD5(-), CD7(+), CD16(-), CD56(+), CD57(-), CD103(+), T-cell intracellular antigen 1(+), and betaF1(+)) that is comparable to that of a newly identified subset of intraepithelial T cells. The tumor progressed rapidly and the patient died within 6 months after the onset of the disease. We recommend a large monoclonal antibody panel for the differential diagnosis of this heterogeneous group of T-cell lymphoma.
Asunto(s)
Neoplasias Intestinales/patología , Células Asesinas Naturales/patología , Linfoma de Células T/patología , Anciano , Antígenos CD/análisis , Biomarcadores de Tumor/análisis , Enfermedad Celíaca/diagnóstico , Diagnóstico Diferencial , Resultado Fatal , Humanos , Inmunofenotipificación , Neoplasias Intestinales/química , Células Asesinas Naturales/química , Linfoma de Células T/química , Masculino , Subgrupos de Linfocitos T/química , Subgrupos de Linfocitos T/patologíaRESUMEN
The oncogene c-Maf was recently found to be overexpressed in approximately 50% of multiple myeloma cases, and a role for c-Maf in promoting cyclin D2 expression has been postulated. We previously examined c-Maf expression in various T-cell lymphomas by reverse-transcription polymerase chain reaction and found extremely elevated c-Maf levels in angioimmunoblastic T-cell lymphoma (AILT). In this study, we examined T-cell lymphomas for c-Maf and cyclin expression immunohistochemically. Of 93 cases of T-cell lymphomas we investigated in the current study, c-Maf expression was seen in 23 out of 31 cases of AILT, 3 out of 11 of adult T-cell leukemia/lymphoma, 4 out of 19 of peripheral T-cell lymphoma, unspecified [PTCL(U)], and 0 out of 11 cases of mycosis fungoides, 0 out of 11 of anaplastic large cell lymphoma, and 1 out of 10 of extranodal NK/T-cell lymphoma, nasal type. Double immunostaining in AILT revealed that the majority of c-Maf-positive cells were also positive for CD43 (MT1), CD45RO (UCHL-1), and CD4 but were negative for CD20 (L26). Additionally, cyclins D1 and D2, which stimulate cell cycle progression, were overexpressed in a large number of the c-Maf-positive AILT samples. Quantitative reverse-transcription polymerase chain reaction analysis also showed that c-Maf was overexpressed in 8/31 cases of AILT, 0/19 cases of PTCL(U), 0/11 cases of anaplastic large cell lymphoma, 0/10 cases of extranodal NK/T-cell lymphoma, nasal type, and 2/8 cases of multiple myeloma, presenting significant difference between AILT and PTCL(U) (P=0.016, chi test). These findings strongly suggest that CD4-positive neoplastic T cells in AILT show c-Maf expression and provide new insight into the pathogenesis of AILT suggesting c-Maf to be a useful diagnostic marker for AILT.
Asunto(s)
Biomarcadores de Tumor/análisis , Linfadenopatía Inmunoblástica/metabolismo , Linfoma de Células T/química , Proteínas Proto-Oncogénicas c-maf/análisis , Adulto , Antígenos CD20/análisis , Biomarcadores de Tumor/genética , Antígenos CD4/análisis , Ciclina D , Ciclina D2 , Ciclinas/análisis , Humanos , Linfadenopatía Inmunoblástica/genética , Linfadenopatía Inmunoblástica/patología , Inmunohistoquímica , Antígenos Comunes de Leucocito/análisis , Leucosialina/análisis , Linfoma de Células T/genética , Linfoma de Células T/patología , Proteínas Proto-Oncogénicas c-maf/genética , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Regulación hacia ArribaRESUMEN
Doxorubicin is one of the most potent anti-tumor drugs with a broad spectrum of use. To reduce its toxic effect and improve its pharmacokinetics, we conjugated it to an HPMA copolymer carrier that enhances its passive accumulation within solid tumors via the EPR effect and decreases its cytotoxicity to normal, noncancer cells. In this study, we compared the antiproliferative, pro-survival, and death signals triggered in EL-4 cancer cells exposed to free doxorubicin and doxorubicin conjugated to a HPMA copolymer carrier via either enzymatically (PK1) or hydrolytically (HYD) degradable bonds. We have previously shown that the intracellular distribution of free doxorubicin, HYD, and PK1 is markedly different. Here, we demonstrated that these three agents greatly differ also in the antiproliferative effect and cell death signals they trigger. JNK phosphorylation sharply increased in cells treated with HYD, while treatment with free doxorubicin moderately decreased and treatment with PK1 even strongly decreased it. On the other hand, treatment with free doxorubicin greatly increased p38 phosphorylation, while PK1 and HYD increased it slightly. PK1 also significantly increased ERK phosphorylation, while both the free doxorubicin and HYD conjugate slightly decreased it. Long-term inhibition of JNK significantly increased both proliferation and viability of EL-4 cells treated with free doxorubicin, showing that the JNK signaling pathway could be critical for mediating cell death in EL-4 cells exposed to free doxorubicin. Both activation of caspase 3 and decreased binding activity of the p50 subunit of NFkappaB were observed in cells treated with free doxorubicin and HYD, while no such effects were seen in cells incubated with PK1. Analysis of the expression of genes involved in apoptosis and regulation of the cell cycle demonstrated that free doxorubicin and HYD have very similar mechanisms of action, while PK1 has very different characteristics.
Asunto(s)
Acrilamidas/farmacología , Doxorrubicina/farmacología , Linfoma de Células T/metabolismo , Acrilamidas/análisis , Acrilamidas/química , Animales , Apoptosis/genética , Caspasa 3/metabolismo , Ciclo Celular/genética , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular , Doxorrubicina/análisis , Doxorrubicina/química , Citometría de Flujo , Expresión Génica/efectos de los fármacos , Concentración 50 Inhibidora , Linfoma de Células T/química , Ratones , Quinasas de Proteína Quinasa Activadas por Mitógenos/antagonistas & inhibidores , Quinasas de Proteína Quinasa Activadas por Mitógenos/metabolismo , FN-kappa B/metabolismo , FosforilaciónRESUMEN
Marek's disease (MD) in the chicken, caused by the highly infectious MD alpha-herpesvirus (MDV), is both commercially important and a unique, naturally occurring model for human T-cell lymphomas overexpressing the Hodgkin's disease antigen, CD30. Here, we used proteomics as a basis for modeling the molecular functions and biological processes involved in MDV-induced lymphomagenesis. Proteins were extracted from an MDV-transformed cell line and were then identified using 2-D LC-ESI-MS/MS. From the resulting 3870 cellular and 21 MDV proteins we confirm the existence of 3150 "predicted" and 12 "hypothetical" chicken proteins. The UA-01 proteome is proliferative, differentiated, angiogenic, pro-metastatic and pro-immune-escape but anti-programmed cell death, -anergy, -quiescence and -senescence and is consistent with a cancer phenotype. In particular, the pro-metastatic integrin signaling pathway and the ERK/MAPK signaling pathways were the two predominant signaling pathways represented. The cytokines, cytokine receptors, and their related proteins suggest that UA-01 has a regulatory T-cell phenotype.